Friday, 20 Oct 2017

You are here

FDA Approves Abaloparatide for High Risk Patients

On April 28th the Food and Drug Administration (FDA) approved abaloparatide (trade name Tymlos) for postmenopausal women with osteoporosis at high risk for fracture due to a history of osteoporotic fracture.  High Risk patients are defined as those with a history of prior osteoporotic fractures, multiple risk factors for fracture, or those unable to take other osteoporosis agents.  (Package insert: http://buff.ly/2pouOOP)

Medscape has reviewed this anabolic agent.  It is intended for high risk postmenopausal women with osteoporosis and is given as a daily 80 μg subcutaneous injection (usually admnistered in the periumbilical region). 

FDA approval is based on results the 18 month ACTIVE trial that included > 2000 women, subcutaneous and showed an 86% reduction in vertebral fractures and 43% reduction nonvertebral fractures.

The product label contains a boxed warning noting that the drug caused a dose-dependent increase in the incidence of osteosarcoma in rats. The effect was observed at systemic exposures to abaloparatide ranging from 4 to 28 times the exposure in humans receiving the 80-μg dose. Whether abaloparatide will cause osteosarcoma in humans is unknown.

Abaloparatide is contraindicated in those with osteosarcoma, Paget's disease, unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external-beam or implant radiation therapy to the skeleton.

As with Forteo (teraparatide), there is a 2 year lifetime limit on use because of these unknown risks. 

Abaloparatide will be available in the United States in June 2017.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Zilretta - a New Drug FDA Approved for Osteoarthritis of the Knee

Flexion Therapeutics announced friday that the U.S. Food and Drug Administration (FDA) has approved its osteoarthritis (OA) of the knee injectable steroid drug Zilretta with the indication of moderate-to-severe knee pain.

Zilretta is the commonly used triamcinolon acetonide combined with a drug delivery system designed to provide extended pain relief over three months.

UAB Researchers Shed Light on Age-Related Osteoporosis

Researchers from the University of Alabama at Birmingham (UAB) have detailed mechanisms leading to age-related bone loss and osteoporosis.

Osteoporotic Fractures as Back Pain in Older Men

The Journal of Bone and Mineral Research reports that older men with undiagnosed vertebral fractures are likely to report new or worsening back pain. (Citation source bit.ly/2y9rMiZ)

Romosuzumab Followed by Alendronate is Best in Fracture Prevention

The NEJM reports that in high risk post-menopausal women, romosozumab for 12 months followed by alendronate resulted in a significantly lower fracture than alendronate alone. 

Bad Knees Through the Ages

The average American today is twice as likely to be diagnosed with knee osteoarthritis as in the years before World War II, Harvard scientists say. And the reasons are less clear than you might think.

Based on a study of more than 2,000 skeletons from cadaveric and archaeological collections across the United States, a Harvard report is the first to definitively show that knee osteoarthritis prevalence has dramatically increased in recent decades.